Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF

Kimio Uchiyama, Manabu Yamada, Yuusuke Shiiba, Shingo Kasazaki, Kenichirou Suga, Hiroshi Iwabuchi, Seiji Asoda, Keita Uehara

Research output: Contribution to journalArticle

Abstract

The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF).The incidence rate of nausea in the aprepitant group was 60%(6/10), and that in the fosaprepitant group was 90%(9/10).The incidence rate of continuous nausea for more than 2 days was significantly lower in the aprepitant group than in the fosaprepitant group(40%[4/10]vs 90%[9/10], p=0.02; c 2 test).In addition, the mean area under the curve of the chronological changes in the grade of nausea tended to be lower in the aprepitant group than in the fosaprepitant group.In both groups, 3 cases(30%)of vomiting were observed.However, the incidence of continued daily vomiting tended to be lower in the aprepitant group than in the fosaprepitant group.These results suggest that aprepitant is more effective than fosaprepitant for nausea induced by TPF.

Original languageEnglish
Pages (from-to)585-589
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume44
Issue number7
Publication statusPublished - 2017 Jul 1

Fingerprint

fosaprepitant
aprepitant
Mouth Neoplasms
Combination Drug Therapy
Nausea
docetaxel
Vomiting
Incidence
Fluorouracil
Cisplatin
Area Under Curve

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF. / Uchiyama, Kimio; Yamada, Manabu; Shiiba, Yuusuke; Kasazaki, Shingo; Suga, Kenichirou; Iwabuchi, Hiroshi; Asoda, Seiji; Uehara, Keita.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 44, No. 7, 01.07.2017, p. 585-589.

Research output: Contribution to journalArticle

Uchiyama, Kimio ; Yamada, Manabu ; Shiiba, Yuusuke ; Kasazaki, Shingo ; Suga, Kenichirou ; Iwabuchi, Hiroshi ; Asoda, Seiji ; Uehara, Keita. / Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2017 ; Vol. 44, No. 7. pp. 585-589.
@article{1245ef88bd36433c8bf749b13f60dfd4,
title = "Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF",
abstract = "The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF).The incidence rate of nausea in the aprepitant group was 60{\%}(6/10), and that in the fosaprepitant group was 90{\%}(9/10).The incidence rate of continuous nausea for more than 2 days was significantly lower in the aprepitant group than in the fosaprepitant group(40{\%}[4/10]vs 90{\%}[9/10], p=0.02; c 2 test).In addition, the mean area under the curve of the chronological changes in the grade of nausea tended to be lower in the aprepitant group than in the fosaprepitant group.In both groups, 3 cases(30{\%})of vomiting were observed.However, the incidence of continued daily vomiting tended to be lower in the aprepitant group than in the fosaprepitant group.These results suggest that aprepitant is more effective than fosaprepitant for nausea induced by TPF.",
author = "Kimio Uchiyama and Manabu Yamada and Yuusuke Shiiba and Shingo Kasazaki and Kenichirou Suga and Hiroshi Iwabuchi and Seiji Asoda and Keita Uehara",
year = "2017",
month = "7",
day = "1",
language = "English",
volume = "44",
pages = "585--589",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "7",

}

TY - JOUR

T1 - Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF

AU - Uchiyama, Kimio

AU - Yamada, Manabu

AU - Shiiba, Yuusuke

AU - Kasazaki, Shingo

AU - Suga, Kenichirou

AU - Iwabuchi, Hiroshi

AU - Asoda, Seiji

AU - Uehara, Keita

PY - 2017/7/1

Y1 - 2017/7/1

N2 - The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF).The incidence rate of nausea in the aprepitant group was 60%(6/10), and that in the fosaprepitant group was 90%(9/10).The incidence rate of continuous nausea for more than 2 days was significantly lower in the aprepitant group than in the fosaprepitant group(40%[4/10]vs 90%[9/10], p=0.02; c 2 test).In addition, the mean area under the curve of the chronological changes in the grade of nausea tended to be lower in the aprepitant group than in the fosaprepitant group.In both groups, 3 cases(30%)of vomiting were observed.However, the incidence of continued daily vomiting tended to be lower in the aprepitant group than in the fosaprepitant group.These results suggest that aprepitant is more effective than fosaprepitant for nausea induced by TPF.

AB - The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF).The incidence rate of nausea in the aprepitant group was 60%(6/10), and that in the fosaprepitant group was 90%(9/10).The incidence rate of continuous nausea for more than 2 days was significantly lower in the aprepitant group than in the fosaprepitant group(40%[4/10]vs 90%[9/10], p=0.02; c 2 test).In addition, the mean area under the curve of the chronological changes in the grade of nausea tended to be lower in the aprepitant group than in the fosaprepitant group.In both groups, 3 cases(30%)of vomiting were observed.However, the incidence of continued daily vomiting tended to be lower in the aprepitant group than in the fosaprepitant group.These results suggest that aprepitant is more effective than fosaprepitant for nausea induced by TPF.

UR - http://www.scopus.com/inward/record.url?scp=85029668106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029668106&partnerID=8YFLogxK

M3 - Article

C2 - 28790262

AN - SCOPUS:85029668106

VL - 44

SP - 585

EP - 589

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -